Central Nervous System Relapse in T and NK cell Lymphomas

Area of Science:

• Hematology
• Oncology
• Neurology

Background:

• T and NK cell lymphomas are rare, aggressive non-Hodgkin lymphomas with high mortality.
• Central nervous system (CNS) involvement in these lymphomas is associated with significant morbidity and dismal outcomes.
• Current management strategies for CNS relapse are largely based on data from B cell neoplasms, lacking specific guidelines for T/NK cell lymphomas.

Purpose of the Study:

• To review the epidemiology of CNS relapse in T and NK cell lymphomas.
• To critically analyze existing literature on prophylaxis and treatment for CNS involvement.
• To highlight the need for standardized care and novel therapeutic approaches.

Main Methods:

• Literature review of retrospective studies and case reports concerning CNS relapse in T/NK cell lymphomas.
• Analysis of risk factors, including extranodal sites and specific disease subtypes.
• Evaluation of current prophylactic and therapeutic options, including novel agents.

Main Results:

• CNS relapse in T/NK cell lymphomas is associated with poor prognosis and lacks a standard of care.
• Retrospective studies are limited by small sample sizes and heterogeneity.
• Extranodal involvement and specific subtypes are identified as risk factors for CNS relapse.
• Evidence supporting CNS-directed prophylaxis is currently insufficient.
• Novel agents show potential for CNS activity, offering promising therapeutic avenues.

Conclusions:

• There is an urgent need for collaborative research to define optimal strategies for CNS disease in T/NK cell lymphomas.
• Targeted agents may offer advantages over traditional cytotoxic therapies for CNS involvement.
• Developing standardized approaches is crucial to improve outcomes for patients with CNS relapse.